லூக் பெர்த்தியாம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from லூக் பெர்த்தியாம். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In லூக் பெர்த்தியாம் Today - Breaking & Trending Today

Reportable, Inc.: Health Canada Clears Pacylex Pharmaceuticals for New Phase 1 Clinical Trial to Evaluate PCLX-001 Capsules in the Treatment of Hematologic and Solid Tumor Cancers


Reportable, Inc.: Health Canada Clears Pacylex Pharmaceuticals for New Phase 1 Clinical Trial to Evaluate PCLX-001 Capsules in the Treatment of Hematologic and Solid Tumor Cancers
Key Takeaways:
Scientists at the University of Alberta have recently published evidence that a new drug could work in blood cancers by targeting B-cell signaling.
Scientists at the University of Alberta also published a study showing potential in breast cancer.
PCLX-001 led to significant tumor regression in mouse models, including completely eliminating lymphoma tumors derived from a patient whose cancer had stopped responding to the standard therapies CHOP and Roche s Rituxan.
Click image above to view full announcement. ....

Kostenloser Wertpapierhandel , Roche Rituxan , Luc Berthiaume , University Of Alberta , Alberta Newsfile Corp , University Of Dundee , லூக் பெர்த்தியாம் , பல்கலைக்கழகம் ஆஃப் ஆல்பர்ட்டா , பல்கலைக்கழகம் ஆஃப் டண்டீ ,

New drug target valid for breast cancer as well as lymphoma


New drug target valid for breast cancer as well as lymphoma
One more piece of the puzzle has fallen into place behind a new drug whose anti-cancer potential was developed at the University of Alberta and is set to begin human trials this year, thanks to newly published research.
The results provide more justification and rationale for starting the clinical trial in May. It s another exciting stepping stone to finding out if this is going to be a new cancer treatment.
John Mackey, First Author, Professor and Director of Oncology Clinical Trials, Faculty of Medicine & Dentistry, University of Alberta
The drug PCLX-001 is designed to selectively kill cancer cells by targeting enzymes involved in myristoylation, a process key to the cell signaling system that is often defective in cancer cells. The molecule was originally developed by the University of Dundee as a treatment for African sleeping sickness. U of A cell biologist Luc Berthiaume was the first to realize it ....

John Mackey , Luc Berthiaume , Emily Henderson , Cross Cancer Institute In Edmonton , University Of Alberta , Alberta Cancer Foundation , Cure Cancer Foundation , University Of Dundee , Pacylex Pharmaceuticals , Cross Cancer Institute , Cure Cancer , Cancer Treatment , Breast Cancer , Clinical Trial , ஜான் மேக்கி , லூக் பெர்த்தியாம் , எமிலி ஹென்டர்சன் , குறுக்கு புற்றுநோய் நிறுவனம் இல் எட்மண்டன் , பல்கலைக்கழகம் ஆஃப் ஆல்பர்ட்டா , ஆல்பர்ட்டா புற்றுநோய் அடித்தளம் , குணப்படுத்த புற்றுநோய் அடித்தளம் , பல்கலைக்கழகம் ஆஃப் டண்டீ , குறுக்கு புற்றுநோய் நிறுவனம் , குணப்படுத்த புற்றுநோய் , புற்றுநோய் சிகிச்சை , மார்பக புற்றுநோய் ,